Core Viewpoint - The company expects a net profit of approximately RMB 1.85 billion for the six months ending June 30, 2025, compared to a net profit of approximately RMB 1.491 billion for the six months ending June 30, 2024, indicating a significant increase in profitability driven by licensing fee income from Novo Nordisk [1] Financial Performance - The anticipated net profit for the first half of 2025 is RMB 1.85 billion, which represents an increase from the RMB 1.491 billion net profit reported for the same period in 2024 [1] - The increase in net profit is primarily attributed to licensing fee income of approximately RMB 1.1 billion from Novo Nordisk [1] - However, there is a decline in segment profits, with intermediate products experiencing a decrease of approximately RMB 430 million and raw materials seeing a decline of approximately RMB 270 million, partially offsetting the overall profit growth [1]
联邦制药(03933)发盈喜，预期中期净溢利约为18.5亿元 同比上升